Why methylphenidate is not successful in cocaine-dependent ADHD patients: a SPECT study comparing DAT before and after methylphenidate treatment in ADHD patients with and without cocaine dependence
- Conditions
- verslavingADHDhyperactivity disorder
- Registration Number
- NL-OMON33367
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 60
1. Male, age 18-60 years;
2. Current DSM-IV diagnosis of adult ADHD for all participants;
3. For the ADHD+cocaine dependent group: Current DSM-IV diagnosis of cocaine dependence, but abstinent from cocaine use for at least 1 week;
4. Able to provide written informed consent and to comply with all study procedures;
5. Negative urine analyses for methylphenidate, amphetamines and cocaine.
1. Currently dependent on any substance other than cocaine or nicotine;
2. History of severe depression, i.e. depression necessitating hospitalization, a history of 2 or more recurrent episodes of depression or previous suicide attempts;
3. Severe neurological or psychiatric disorders or diseases (e.g., psychosis, bipolar depression, Parkinson*s disease, or dementia) that require psychotropic or ECG abnomedications;
4. Serious medical illnesses that would make participation hazardous, such as cardiovascular disease;
5. Known hypersensitivity or allergy to methylphenidate;
6. Under therapy with drug known to influence binding to DATs, including antipsychotics, MPH, bupropion, and dexamphetamine within 30 days prior to randomization;
7. Received a drug with known potential for toxicity to a major organ system within the month prior to entering treatment;
8. Clinically significant abnormal laboratory values (*3x normal) as measured by the treatment center;
9. Any disease of the gastrointestinal system, liver, or kidneys which could result in altered metabolism or excretion of the study medication;
10. Hypersensitivity to Iodine.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Does baseline DAT binding differ in ADHD+SUD and ADHD-SUD patients?<br /><br>Does MPH affect DAT binding differently in ADHD+SUD and ADHD-SUD patients?</p><br>
- Secondary Outcome Measures
Name Time Method <p>Does MPH differentially affect ADHD symptoms and ADHD associated cognitive<br /><br>functions in ADHD patients with and without cocaine dependence?<br /><br>Does DAT occupancy affect drug craving and drug use in ADHD+SUD patients? </p><br>